T1	intervention 37 73	Palbociclib in Addition to Letrozole
T2	eligibility 430 521	Postmenopausal women with ER-positive primary BC and tumors greater than or equal to 2.0 cm
T3	control 556 565	letrozole
T8	total-participants 1339 1358	Three hundred seven
T9	outcome 1384 1401	Clinical response
T10	outcome 1501 1537	complete response + partial response
T11	iv-bin-percent 1539 1544	54.3%
T12	cv-bin-percent 1547 1552	49.5%
T13	outcome 1559 1578	progressive disease
T14	iv-bin-percent 1583 1587	3.2%
T15	cv-bin-percent 1595 1599	5.4%
T17	outcome 1888 1923	achieved complete cell-cycle arrest
T18	iv-bin-percent 1925 1928	90%
T19	cv-bin-percent 1931 1934	59%
T20	outcome 1947 2023	Median log-fold change (suppression) of cleaved poly (ADP-ribose) polymerase
T21	outcome 2130 2157	grade 3 or greater toxicity
T22	iv-bin-percent 2189 2194	49.8%
T23	cv-bin-percent 2197 2202	17.0%
T4	outcome 1615 1646	Median log-fold change in Ki-67
T5	iv-cont-median 1716 1720	-4.1
T6	cv-cont-median 1723 1727	-2.2
T16	iv-cont-median 2086 2091	-0.80
T24	cv-cont-median 2094 2099	-0.42
T7	outcome-Measure 1026 1041	change in Ki-67
